Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Benoit de Renzis , Veronique Mansat-De Mas , Eric Wattel , Odile Beyne-Rauzy , Laurent Knoops , Aurélie Cabrespine , Zahia Azgui , Lionel Ades , Jean-Jacques Kiladjian , Pierre Fenaux While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p<.0011) and better overall survival (OS, p=.011). OS difference persisted after matching on age, sex, IPSS and % marrow blast (p=.031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome.

Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research